Can Reni-cel help Editas take the SCD / TDT gene therapy lead? What could be its pricing strategy? [Video]

Greetings, fellow investors! Welcome back to ShareTreck. I’m Raj, and today,
I will talk further about a hidden nugget in the Editas earnings report that I reported in the last video on Editas. Today I compare the gene targets, edit methodology and arrive at conclusions about potential superiority and pricing strategy of Reni-cel.

Technical analysis may not always be reliable.

JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter. For a low price of 10 cents per day or $2.99 per month, you can show your appreciation for my work & the channel.

https://www.youtube.com/channel/UCLfA-8l-TE2n-VH-WBKycEg/join

Please subscribe: https://www.youtube.com/channel/UCLfA-8l-TE2n-VH-WBKycEg?sub_confirmation=1

The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
Disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.